compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has
been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any
tumor cells that remain after surgery. It is not yet known whether sunitinib malate is more
effective than sorafenib tosylate or placebo in treating kidney cancer.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.